Innovative Industrial Properties (IIPR) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
14 Oct, 2025Key financial and operational highlights
$2.5B total committed/invested capital across 108 properties in 19 states, with $62.9M Q2 2025 revenue and a $7.60 annualized dividend per share as of June 30, 2025.
Weighted average lease length is 13.1 years, with 9.0M rentable square feet and annual escalations built into leases.
Portfolio is diversified by geography and tenant, with top 10 states accounting for 89.6% of annualized base rent and 90% of properties classified as industrial.
Top tenants include PharmaCann, AWH, Green Thumb, and Curaleaf, with 65% of tenants public and 89% multi-state operators.
Balance sheet remains strong with 11% debt to total gross assets, $192M+ liquidity, and an undrawn $87.5M credit facility.
Business model and strategy
Focuses on long-term, triple-net leases (15–20 years) with parent company guarantees and no recurring capital expenditures for the landlord.
Provides sale-leasebacks and funds improvements for cultivation, processing, and retail properties, aligning closely with state-licensed cannabis operators.
Attractively priced financing maximizes tenant access to capital and supports their growth plans.
Diligent underwriting and ongoing monitoring of tenants, including financial reviews and operational meetings.
Market and industry trends
U.S. legal cannabis sales reached $31.4B in 2024, projected to grow to $44B by 2029, a 7% CAGR.
79% of Americans live in a county where marijuana is legal for medical or recreational use; 54% live in a state with legal recreational use.
Cannabis tax revenue totaled $24.7B since 2014, with $4.4B collected in 2024 alone; in some states, cannabis tax revenue exceeds alcohol taxes.
Increasing institutional adoption, with ~13% of FDIC banks offering services to marijuana-related businesses in 2024.
Latest events from Innovative Industrial Properties
- 2025 revenues hit $266M; life sciences investment and leasing drive growth amid tenant challenges.IIPR
Q4 202524 Feb 2026 - Q2 revenue up 4% to $79.8M, AFFO $2.29/share, 95.6% leased, and dividend up 4.4%.IIPR
Q2 20242 Feb 2026 - Q3 2024 revenue was $76.5M, AFFO $64.3M, and portfolio was 95.7% leased.IIPR
Q3 202415 Jan 2026 - 2024 revenue steady at $308.5M; strong liquidity, high occupancy, and PharmaCann lease resolution.IIPR
Q4 202423 Dec 2025 - 2024 saw record revenue, strong governance, and enhanced ESG and compensation practices.IIPR
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all.IIPR
Proxy Filing1 Dec 2025 - Q1 2025 revenue and net income fell on tenant defaults, but liquidity and leasing remain strong.IIPR
Q1 202524 Nov 2025 - Q2 2025 revenue and AFFO fell sharply, but liquidity is strong and IQHQ investment boosts outlook.IIPR
Q2 202523 Nov 2025 - Q3 2025 revenue fell 15% to $64.7M as tenant defaults hit, but life sciences diversification advanced.IIPR
Q3 202513 Nov 2025